Werewolf Therapeutics Inc

-0.12 (-6.86%)
7:43:52 PM EDT: $1.68 +0.05 (+3.07%)
Earnings Announcements

Werewolf Therapeutics Reports Q3 2022 Results

Published: 11/10/2022 12:34 GMT
Werewolf Therapeutics Inc (HOWL) - Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update.
Remains Well-capitalized With Runway That Will Carry Co Through at Least Q2 of 2024.
Werewolf Therapeutics - As of September 30, 2022, Cash and Cash Equivalents Decreased to $140.5 Million, Compared to $157.5 Million As of December 31, 2021.
Qtrly Loss per Share $0.40.
Q3 Earnings per Share View $-0.60 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $2.07 Million
Adjusted EPS is expected to be -$0.55

Next Quarter Revenue Guidance is expected to be $5 Million
Next Quarter EPS Guidance is expected to be -$0.50

More details on our Analysts Page.